Capvaxive is a vaccine to protect adults against pneumonia (infection of the lungs) and invasive disease caused by the bacterium Streptococcus pneumoniae (S. pneumoniae). It is also used in adolescents and children from two years of age who previously completed a primary pneumococcal vaccination regimen for children. Invasive disease occurs when the bacterium spreads through the body, causing conditions such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spine). Capvaxive contains parts from 21 different types of S. pneumoniae.
Therapeutic Indication
Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in children and adolescents 2 to less than 18 years of age who previously completed a primary paediatric pneumococcal vaccination regimen. See sections 4\.4 and 5\.1 for information on protection against specific pneumococcal serotypes. The use of Capvaxive should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07AL02
ATC Item
N/A
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
EMA Name
Capvaxive
Medicine Name
Capvaxive
Aliases
N/ANo risk management plan link.
